Systems and methods for interior energy-activation from an exterior source

Patent metadata

Field	Value
Publication number	US-9498643-B2
Application number	US-201514932435-A
Country	US
Kind code	B2
Filing date	Nov 4, 2015
Priority date	Apr 8, 2007
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

First claim

The invention claimed is:

1. A method for treating a condition, disorder or disease comprising:
providing an activation energy sufficient to cause a predetermined change in a subject, wherein the activation energy is generated in-situ in said subject by application of an initiation energy which is converted in-situ to said activation energy, wherein the initiation energy is at least one member selected from the group consisting of x-rays, gamma rays, and electron beams; and
prior to or simultaneously with providing the activation energy, administering to the subject at least one activatable pharmaceutical agent that is activatable in situ by the activation energy, wherein upon activation, the activated at least one activatable pharmaceutical agent effects the predetermined change in the subject,
wherein said predetermined change at least one of 1) causes a change in organism activity or 2) treats the condition, disorder, or disease.

2. The method of claim 1 , further comprising, prior to said applying of the initiation energy, administering to the subject at least one energy modulation agent that assists in converting the initiation energy to the activation energy.

3. The method of claim 2 , wherein the at least one energy modulation agent comprises one or more selected from a biocompatible fluorescing metal nanoparticle, fluorescing dye molecule, gold nanoparticle, a water soluble quantum dot encapsulated by polyamidoamine dendrimers, a luciferase, a biocompatible phosphorescent molecule, a combined electromagnetic energy harvester molecule, and a lanthanide chelate capable of intense luminescence.

4. The method of claim 2 , wherein the energy modulation agent comprises a fluorophore.

5. The method of claim 2 wherein the at least one energy modulation agent comprises a single energy modulation agent, and is coupled to said at least one activatable pharmaceutical agent.

6. The method of claim 1 , wherein the initiation energy source is selected from the group consisting of x-rays and electron beams.

7. The method of claim 1 , wherein the initiation energy produces energy states for energy transfer to the at least one activatable pharmaceutical agent.

8. The method of claim 1 , wherein the initiation energy is directed at a solid tumor.

9. The method of claim 1 , wherein the initiation energy directly or indirectly activates the at least one activatable pharmaceutical agent.

10. The method of claim 1 , wherein the initiation energy directly or indirectly activates a psoralen.

11. The method of claim 10 , wherein the initiation energy directly or indirectly activates 8-MOP or AMT.

12. The method of claim 11 , wherein the initiation energy damages DNA in target cells.

13. The method of claim 1 , wherein the initiation energy comprises ionizing radiation which interacts to produce reactive groups at a target site.

14. The method of claim 13 , wherein the reactive groups comprise at least a member selected from the group consisting of ions, singlet oxygen, free radicals, and hydroxides.

15. The method of claim 1 , wherein the predetermined change is a predetermined cellular change.

16. The method of claim 15 , wherein said condition, disorder or disease is a cell proliferation disorder and said predetermined cellular change treats the cell proliferation disorder by causing an increase or decrease in cell proliferation rate of a target cell.

17. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is activated by one or more sequential single photon absorption events.

18. The method of claim 1 , wherein the at least one activatable pharmaceutical agent comprises an active agent contained within a photocage, wherein upon exposure to said initiation energy, the photocage disassociates from the active agent, rendering the active agent available.

19. The method of claim 1 , wherein the at least one activatable pharmaceutical agent comprises an active agent contained within a photocage, and said activation energy is UV-A or visible energy, wherein upon exposure to said UV-A or visible energy, the photocage disassociates from the active agent, rendering the active agent available.

20. The method of claim 1 , the activation energy is capable of penetrating human tissue up to about 4 mm.

21. The method of claim 1 , wherein the at least one activated pharmaceutical agent causes an auto-vaccine effect in the subject that reacts with a target cell.

22. The method of claim 1 , wherein the predetermined cellular change is apoptosis in a target cell.

23. The method of claim 1 , wherein the disorder is at least one member selected from the group consisting of cancer, bacterial infection, viral infection, immune rejection response, autoimmune disorders, and aplastic conditions.

24. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is a photoactivatable agent.

25. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is selected from psoralens, pyrene cholesteryloleate, acridine, porphyrin, fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metal complexes of bleomycin, transition metal complexes of deglycobleomycin organoplatinum complexes, alloxazines, vitamin Ks, vitamin L, vitamin metabolites, vitamin precursors, naphthoquinones, naphthalenes, naphthols and derivatives thereof having planar molecular conformations, porphyrins, dyes and phenothiazine derivatives, coumarins, quinolones, quinones, and anthroquinones.

26. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is a psoralen, a coumarin, or a derivative thereof.

27. The method of claim 26 , wherein the at least one activatable pharmaceutical agent is 8-MOP or AMT.

28. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is one selected from 7,8-dimethyl-10-ribityl, isoalloxazine, 7,8,10-trimethylisoalloxazine, 7,8-dimethylalloxazine, isoalloxazine-adenine dinucleotide, alloxazine mononucleotide, aluminum (III) phthalocyanine tetrasulonate, hematoporphyrin, and phthadocyanine.

29. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is coupled to a carrier that is capable of binding to a receptor site.

30. The method of claim 29 , wherein the carrier is one selected from insulin, interleukin, thymopoietin or transferrin.

31. The method of claim 30 , wherein the at least one activatable pharmaceutical agent is coupled to the carrier by a covalent bond.

32. The method of claim 30 , wherein the at least one activatable pharmaceutical agent is coupled to the carrier by a non-covalent bond.

33. The method of claim 30 , wherein the receptor site is one selected from nucleic acids of nucleated cells, antigenic sites on nucleated cells, or epitopes.

34. The method of claim 1 , wherein the at least one activatable pharmaceutical agent has affinity for a target cell.

35. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is capable of being preferentially absorbed by a target cell.

36. The method of claim 1 , wherein the at least one activatable pharmaceutical agent is a DNA intercalator or a halogenated derivative thereof.

37. The method o

Assignees

• Immunolight Llc
• Immunolight Llc

Inventors

• Bourke Jr Frederic A

Classifications

• A61P7/08

  Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61L2/088

  using photocatalysts or photosensitisers · CPC title